中文在线а√天堂8_91久久久久蛋_日本少妇网站_人妻一区二区三区蜜_大屁股大乳丰满人妻呻吟_国产视频h_综合网啪啪啪_男人扒女人添高潮视频_国产综合久久7777777_国产夜夜操_人妻少妇精品无码专区二区a_人操人_成人精品在线视频_一级片久久久_亚洲人人99五月天

Adiponectin / Acrp30 ELISA Kit, Human

貨號:

 詳細請電詢

  • 詳情
  • 參數
  • 實驗應用
  • 產品說明書
  •  This assay employs the quantitative sandwich enzyme immunoassay technique for the quantitative detection of human Adiponectin. The Human Adiponectin ELISA is for research use only. Not for diagnostic or therapeutic procedures.

     

     

     

     

    Adiponectin, also known as gelatin-binding protein of 28 kDa (GBP-28), adipose most abundant gene transcript 1 (apM1), Adipocyte complement-related protein of 30 kDa (Acrp30), and AdipoQ, is a protein involved in regulating glucose levels as well as fatty acid breakdown. There are four distinct regions of adiponectin: a short signal sequence that targets the hormone for secretion outside the cell, a short region that varies between species, a 65-amino acid region with similarity to collagenous proteins and a globular domain. Adiponectin assembles into different complexes including trimers, hexamers, and higher order oligomeric structures that may affect biological activity. Adiponectin is a protein hormone that modulates a number of metabolic processes, including glucose regulation and fatty acid oxidation and is exclusively secreted from adipose tissue (and also from the placenta in pregnancy) into the bloodstream and is very abundant in plasma relative to many hormones. Adiponectin may also play anti-atherogenic and anti-inflammatory roles, and negatively regulates myelomonocytic progenitor cell growth and TNF-α production in macrophages. Monitoring of Adiponectin levels in serum provides more detailed insights in several pathological situations such as  type 2 diabetes,  obesity, atherosclerosis and non-alcoholic fatty liver disease (NAFLD).

  •  QQ圖片20160616151618.png

  •  詳細請電詢

  •  詳細請電詢

ICP備案號: 滬ICP備15057650號-1 滬公網安備31011202005471
雷萌生物科技(上海)有限公司 保留所有版權.

首頁   |   產品中心   |   產品應用   |   技術支持   |   新聞中心   |   關于我們   |   ibidi官網
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |